title: The path to an RSV vaccine.
abstract: Respiratory syncytial virus (RSV) is the greatest remaining unmet infant vaccine need in developed countries and an important unmet infant vaccine need worldwide. More than 40 years of effort have yet to result in a licensed RSV vaccine for humans. Key challenges to RSV vaccine development include a peak of severe disease at 2-3 months of age, problematic biochemical behavior of key vaccine antigens, a history of vaccine-mediated disease enhancement, and reliance on animal models that may not accurately reflect human disease processes. Potential paths to overcome these challenges include maternal immunization, structure-based engineering of vaccine antigens, the design of a novel platform for safe infant immunization, and the development of improved animal models for vaccine-enhanced disease.
authors.affiliation: Novartis Vaccines and Diagnostics, Inc., 350 Massachusetts Avenue, Cambridge, MA 02139, United States.
authors.forename: Christine A
authors.initials: CA
authors.lastname: Shaw
authors.forename: Max
authors.initials: M
authors.lastname: Ciarlet
authors.forename: Brian W
authors.initials: BW
authors.lastname: Cooper
authors.forename: Lamberto
authors.initials: L
authors.lastname: Dionigi
authors.forename: Paula
authors.initials: P
authors.lastname: Keith
authors.forename: Karen B
authors.initials: KB
authors.lastname: O'Brien
authors.forename: Maryam
authors.initials: M
authors.lastname: Rafie-Kolpin
authors.forename: Philip R
authors.initials: PR
authors.lastname: Dormitzer
mesh_terms: D000818:Animals; D035843:Biomedical Research / Q000639:trends; D004195:Disease Models, Animal; D006801:Humans; D007223:Infant; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology* / Q000517:prevention & control; D022261:Respiratory Syncytial Virus Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D014611:Vaccination / Q000379:methods
chemical_list: D022261:Respiratory Syncytial Virus Vaccines